AES

Fluence Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares; Raises Gross Proceeds of $998,200,000

Retrieved on: 
Tuesday, November 2, 2021
Other Energy, Utilities, Technology, Other Technology, Alternative Energy, Energy, Hardware, BofA Securities, 2nd Floor (Nina song), Broadridge Financial Solutions, HSBC, Security (finance), U.S. Securities and Exchange Commission, UBS, Varick Street, Credit Suisse, AES, Telephone, USA, Exercise, Morgan Stanley, Nasdaq, LLC, Bank of America, Attention, Prospectus, RBC Capital Markets, Sale, Robert W. Baird, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Energy, Wind, Financial adviser

Proceeds from the initial public offering were $998.2 million, before deducting underwriting discounts and commissions and other offering expenses.

Key Points: 
  • Proceeds from the initial public offering were $998.2 million, before deducting underwriting discounts and commissions and other offering expenses.
  • The shares began trading on the Nasdaq Global Select Market on September 28, 2021 under the ticker symbol "FLNC."
  • J.P. Morgan Securities LLC, Morgan Stanley, Barclays Capital Inc., and BofA Securities are acting as joint lead book-running managers for the offering.
  • Incorporated, Raymond James & Associates, Inc., Seaport Global Securities LLC, Penserra Securities LLC, and Siebert Williams Shank & Co., LLC are acting as co-managers for the offering.

Acadia Pharmaceuticals Presents New Dementia-Related Psychosis Real-World Outcomes Data at Psych Congress 2021

Retrieved on: 
Tuesday, November 2, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Mental Health, Clinical Trials, Other Health, Dyslipidemia, Medical Affairs Bureau, ACAD, Fracture, Patient, PVD, Stroke, Delusion, Senior, Hallucination, Medicare, Atypical, Moyamoya disease, DRP, AES, Nasdaq, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Psych, Hyperlipidemia, Pharmaceutical industry

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021, held virtually and in-person October 29-November 1, 2021 in San Antonio, TX.

Key Points: 
  • Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced today that three data presentations featuring new analyses of Medicare claims data on dementia-related psychosis (DRP) outcomes were presented at Psych Congress 2021, held virtually and in-person October 29-November 1, 2021 in San Antonio, TX.
  • Median annual total costs were nearly two times higher ($29,898) among patients with suboptimal outcomes compared with patients who did not experience suboptimal outcomes ($14,158; p
  • Dementia-related psychosis occurs in many types of dementia, including Alzheimers disease, dementia with Lewy bodies, Parkinsons disease dementia, vascular dementia, and frontotemporal dementia.
  • We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinsons disease psychosis.

Fluence Announces Pricing of Initial Public Offering

Retrieved on: 
Thursday, October 28, 2021
Software, Technology, Energy, Other Energy, BofA Securities, 2nd Floor (Nina song), Broadridge Financial Solutions, HSBC, Security (finance), U.S. Securities and Exchange Commission, UBS, Varick Street, Credit Suisse, AES, Telephone, USA, Morgan Stanley, Nasdaq, LLC, Bank of America, Attention, Prospectus, RBC Capital Markets, Sale, Robert W. Baird, Barclays Capital Inc. v. Theflyonthewall.com, Inc., Wind

Fluence, a leading global provider of energy storage products and services and digital applications for renewables and storage, today announced the pricing of its initial public offering of 31,000,000 shares of its Class A common stock at a price to the public of $28.00 per share.

Key Points: 
  • Fluence, a leading global provider of energy storage products and services and digital applications for renewables and storage, today announced the pricing of its initial public offering of 31,000,000 shares of its Class A common stock at a price to the public of $28.00 per share.
  • The initial public offering is expected to close on November 1, 2021, subject to customary closing conditions.
  • In addition, Fluence has granted the underwriters a 30-day option to purchase up to an additional 4,650,000 shares of its Class A common stock at the initial public offering price, less underwriting discounts and commissions.
  • J.P. Morgan Securities LLC, Morgan Stanley, Barclays Capital Inc., and BofA Securities are acting as joint lead book-running managers for the offering.

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

Retrieved on: 
Wednesday, October 27, 2021
Safety, Șaeș, Phase, PG, Global Assessment of Functioning, CEST, AE, Ulcer, C5a, Patient, FDA, Erysipelas, EDT, PGA, AES, Nasdaq, Hospital, Therapy, GLOBE, Rash, Pharmaceutical industry

JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive data from the third cohort of patients in the Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum (PG).

Key Points: 
  • JENA, Germany, Oct. 27, 2021 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces positive data from the third cohort of patients in the Phase IIa open-label study with vilobelimab in Pyoderma Gangraenosum (PG).
  • We are happy to see more patients responding with the highest dose of vilobelimab in patients with Pyoderma Gangraenosum, commented Dr. Korinna Pilz, Chief Clinical Development Officer of InflaRx.
  • As previously announced, a total of 19 patients were enrolled in the multi-center, proof-of-concept study, with seven patients enrolled in the third cohort.
  • The main objectives of the study are the evaluation of the safety and efficacy of vilobelimab in patients with PG.

AES Ohio commemorates completion of the Smart Operations Center

Retrieved on: 
Tuesday, October 26, 2021
Control center, Commerce, Efficiency, Technology, LinkedIn, AES Corporation, Workforce, Twitter, NYSE, AES, MacGregor Park, ROCC, DPL Inc., Remotely operated underwater vehicle, DPL, PMAC, CEO, Multimedia, Columbus metropolitan area, Ohio, Solution, Dayton Area Rugby Club, Mineral wool, Renewable energy

DAYTON, Ohio, Oct. 26, 2021 /PRNewswire/ -- Leaders of AES Ohio, a subsidiary of The AES Corporation (NYSE: AES), joined state and local officials in a ribbon cutting ceremony to commemorate completion of the AES Smart Operations Center at MacGregor Park.

Key Points: 
  • DAYTON, Ohio, Oct. 26, 2021 /PRNewswire/ -- Leaders of AES Ohio, a subsidiary of The AES Corporation (NYSE: AES), joined state and local officials in a ribbon cutting ceremony to commemorate completion of the AES Smart Operations Center at MacGregor Park.
  • While located here in Dayton, the Smart Operations Center is an integral part of our overall AES global operations," said Bernerd Da Santos, AES EVP and Chief Operating and Infrastructure Officer.
  • Using leading-edge technology, the AES Smart Operations Center will use data analytics and modeling to increase the efficiency of its electric operations across the US.
  • The opening of the AES Smart Operations Center and the recent rebranding of AES and AES Ohio are key pillars in the company's efforts to raise its profile as an innovative, adaptable energy company.

Adtralza® (tralokinumab) Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, October 22, 2021
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Safety, Science, Atopic dermatitis, MD, Leo Pharma, Quality of life, Research, Disease, Poster, Dermatology, Tralokinumab, Ageing, Adolescence, Patient, Overalls, Chair, EASI, Health Canada, LEO, European Commission, Conference, Dermatitis, Royal commission, Adult, DKK, IGA, NRS, Skin, SCORAD, AES, Development, MHRA, Department, Pharmaceutical industry, Vaccine, Copper, Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, the ECZTRA 6 Trial, atopic dermatitis, LEO Pharma, THE ECZTRA 6 TRIAL, ATOPIC DERMATITIS, LEO PHARMA

These findings are encouraging, as moderate-to-severe atopic dermatitis can have major physical and psychosocial impacts on adolescents who have limited options for long-term treatment.

Key Points: 
  • These findings are encouraging, as moderate-to-severe atopic dermatitis can have major physical and psychosocial impacts on adolescents who have limited options for long-term treatment.
  • This is an important milestone for the overall ECZTRA clinical trial program as we expand studies to include younger patients.
  • Paller A. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial.
  • Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no.

Tralokinumab Achieves Primary and Secondary Endpoints in Phase 3 Trial of Adolescents With Moderate-to-Severe Atopic Dermatitis

Retrieved on: 
Friday, October 22, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Safety, Science, Atopic dermatitis, Leo Pharma, Quality of life, Research, Disease, Poster, Dermatology, Ageing, Adolescence, Patient, Overalls, Food, Health Canada, EASI, Tralokinumab, LEO, European Commission, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Dermatitis, Royal commission, Adult, DKK, IGA, NRS, Skin, SCORAD, AES, Development, MHRA, Department, Pharmaceutical industry, Vaccine, Copper, the ECZTRA 6 Trial, atopic dermatitis, LEO Pharma, THE ECZTRA 6 TRIAL, ATOPIC DERMATITIS, LEO PHARMA

These findings are encouraging, as moderate-to-severe atopic dermatitis can have major physical and psychosocial impacts on adolescents who have limited options for long-term treatment.

Key Points: 
  • These findings are encouraging, as moderate-to-severe atopic dermatitis can have major physical and psychosocial impacts on adolescents who have limited options for long-term treatment.
  • This is an important milestone for the overall ECZTRA clinical trial program as we expand studies to include younger patients.
  • Paller A. Efficacy and safety of tralokinumab in adolescents with moderate-to-severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial.
  • Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no.

AmMax Bio Announces Positive Interim Phase 2 Results of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

Retrieved on: 
Wednesday, October 20, 2021
Giant, Pain, AES, Tenosynovial giant cell tumor, Pharmacokinetics, Risk, Cell, Pain management, TGCT, Disability, Macrophage, Idiopathic pulmonary fibrosis, Week, CSF1R, ORR, Oncology, Sarcoma, Incidence, RECIST, Recurrence, Leiden University Medical Center, CSF1, Neoplasm, Quality of life, NAMD, GLOBE, Patient, Magnetic resonance imaging, Infection, IPF, Health, Knee, Principal, Safety, MRI, Pharmaceutical industry, Medical imaging

REDWOOD CITY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- AmMax Bio, Inc. (“AmMax”), a private clinical-stage biotech company developing novel treatments with AMB-05X, its proprietary anti-CSF1R monoclonal antibody platform, today announced positive interim data from a Phase 2 study of AMB-05X for the treatment of tenosynovial giant cell tumor (TGCT).

Key Points: 
  • We are very excited to report these positive interim results of AMB-05X for the treatment of TGCT, said Larry Hsu, Ph.D., Chief Executive Officer of AmMax Bio.
  • We are working closely with our investigators in Europe and the U.S. to complete our Phase 2 program and prepare for a pivotal trial.
  • As a locally-administered, non-surgical treatment, AMB-05X could offer an optimal balance of safety and efficacy as a meaningful treatment option.
  • AmMax is enrolling patients in Phase 2 clinical programs for tenosynovial giant cell tumor (TGCT) and has achieved nonclinical proof-of-concept in both neovascular age-related macular degeneration (nAMD) and idiopathic pulmonary fibrosis (IPF).

Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis

Retrieved on: 
Wednesday, October 20, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Breakthrough therapy, Clinical trial, AES, Pain, Caregiver, Pharynx, Mouth, Șaeș, Head, SAE, Twitter, Patient, Cisplatin, Toxicity, Incidence, KOSDAQ, Chemoradiotherapy, Mucositis, Eating, SOM, Safety, FDA, Management of ulcerative colitis, CEO, Dentistry, Homeostasis, Radiation, Malnutrition, Stage 2, Dehydration, Inflammation, Edwards Lifesciences, Key Stage 1, Hospital, Pharmaceutical industry

Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).
  • EC-18, a novel, first-in-class, small molecule oral immunomodulator, reduced the duration and incidence of severe oral mucositis in patients with head and neck cancer undergoing concurrent chemoradiation therapy.
  • Patients with the most severe form of oral mucositis often have to discontinue or modify their cancer treatment.
  • "We are delighted to announce these positive results from our Phase 2 U.S. study, which confirm that EC-18 is safe and well-tolerated, said Ki-Young Sohn, CEO & Chairman, Enzychem Lifesciences.

Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

Retrieved on: 
Tuesday, October 19, 2021
IND, Virus, Twitter, AML, STS, Antimetabolite, Security (finance), Drug discovery, Terminology, Female, Human, Patient, MAD, Seriousness, Medication, Safety, AES, Pharmacokinetics, Cancer, Private Securities Litigation Reform Act, COVID-19, LinkedIn, ACT Biotech Inc, Drug Quality and Security Act, MHRA, Risk, Vital signs, SEC, Physical examination, Medicines and Healthcare products Regulatory Agency, Liver, Doxorubicin, Volunteering, Glycolysis, Neoplasm, U.S. Securities and Exchange Commission, SAD, Securities Exchange Act of 1934, CEO, T-cell lymphoma, Forward-looking statement, Pancreas, Mouse, Brain, Severe acute respiratory syndrome coronavirus 2, Program, Form 10-K, Acute myeloid leukemia, PK, Securities Act of 1933, Culture, Glycosylation, Company, Pharmaceutical industry, Vaccine

"We are incredibly grateful for the ongoing efforts and discussions the MHRA has engaged in with us to advance this important program.

Key Points: 
  • "We are incredibly grateful for the ongoing efforts and discussions the MHRA has engaged in with us to advance this important program.
  • Coronaviruses, including SARS-CoV-2, are highly dependent upon glycosylation to form structurally and functionally different essential glycoproteins, as well as glycolysis for energy production.
  • The Phase 1a study in healthy human volunteers will investigate the effects of a single ascending dose (SAD) and multiple days of ascending dosing (MAD) of WP1122 administered as an oral solution.
  • Moleculin Biotech is also in the process of identifying additional countries where potential future Phase 2 COVID-19 clinical studies could occur.